about
Growth factor and signaling pathways and their relevance to prostate cancer therapeuticsManagement of patients with biochemical recurrence after local therapy for prostate cancerCombining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapySurvival in men with nonmetastatic prostate cancer treated with hormone therapy: a quantitative systematic review.Prostate angiosarcoma: a case report and literature review.Rheumatoid arthritis masked by docetaxel chemotherapy in a patient with ovarian carcinomaNovel targeted therapeutics for metastatic castration-resistant prostate cancer.Ruthenium-based chemotherapeutics: are they ready for prime time?A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer.Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born.Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer.Enzalutamide: an evidence-based review of its use in the treatment of prostate cancerAngiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examinationNausea and vomiting associated with cancer chemotherapy: drug management in theory and in practiceChanges in PSA kinetics predict metastasis- free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: combined analysis of 4 phase II trialsLong-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National DatabaseEvolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancerProstate angiosarcoma: is there any association with previous radiation therapy?Use of androgen deprivation therapy in prostate cancer: indications and prevalence.Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer.Very-high-risk localized prostate cancer: definition and outcomes.The effect of the frequency and duration of PSA measurement on PSA doubling time calculations in men with biochemically recurrent prostate cancer.Current status of immunological therapies for prostate cancer.Update: immunological strategies for prostate cancer.Future directions in castrate-resistant prostate cancer therapy.Current status of immunological approaches for the treatment of prostate cancerSipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges.The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen deprivation.Abiraterone acetate: a hat trick of clinical benefits.Does short-term ADT before and during radiation therapy improve outcomes in locally advanced prostate cancer?The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancer.Combining active immunotherapy with immune checkpoint blockade for the treatment of advanced prostate cancer.Abiraterone acetate for prostate cancer: a new era of hormonal therapies.Expanding treatment options for metastatic prostate cancerPhase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences.Combining active immunotherapy with immune checkpoint blockade for the treatment of advanced prostate cancer.A cut above.Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer.Efficacy of Abiraterone and Enzalutamide in Pre- and Postdocetaxel Castration-Resistant Prostate Cancer: A Trial-Level Meta-Analysis.AR Signaling in Human Malignancies: Prostate Cancer and Beyond.
P50
Q26827975-FDEB209D-3BBF-4A4A-83AB-EFB742DCE03CQ26849220-D12AC0D3-DEA5-4690-97FE-19BDEB517C8DQ26851608-1A2AB142-356C-47A5-9AFF-758FB2904743Q33304413-C818B12B-5FAF-4F56-A37B-DCFA6022B0FAQ33565834-9D5DC30A-AE7E-48C8-8021-52319DB1EEC1Q33608504-3B97E832-08B0-40FB-9A18-6F922032ABD3Q33642278-76F89C38-9BBD-4A67-808D-BE23626D3852Q34102818-5FE1A301-A0B9-4CAE-8ADD-E789897D0951Q34205971-78E69039-1846-489E-B56A-7F29CBD39239Q34291736-A2B4A0F7-C1CC-4928-AF96-350767761193Q34323756-28ABE032-B5CD-4C2D-B534-638267331CA3Q34339501-20F57F58-64A7-448C-9207-0D1F6CE18DCBQ35219246-3A1B06E1-F0B2-495B-B2BA-898DA85D47A7Q35571607-8ADE0633-0E28-4687-BE38-5C35B1E39B4BQ35656240-489D4512-EFED-4D23-86AE-DEC15BA9F4A3Q36108417-BAC5D2BC-D5BA-4BE6-B2C8-1D5A49D789F6Q36241242-3A96D956-33AB-4D1F-9306-E69E2EE9204FQ37023815-E34A7D1E-FE5B-4E10-B627-FECC75C48F97Q37074379-2B86B970-CF7A-49B9-8EE4-5FB3057EF09EQ37092020-64197C07-1A4A-4681-9D5C-64A3B5E20862Q37623723-9CA66355-54C9-4442-A5D8-BC7D40458096Q37623774-4A711216-67CA-439F-BFDA-5ED513161AEBQ37697477-22F7EB5F-9AE5-4216-B753-F0359A8F870EQ37738797-77569208-B083-4A79-A9BF-25A36E478568Q37826274-C473FF50-4377-4A76-A751-BD3150FE2257Q37983491-5FB5DCCA-B159-4FCA-B00B-5837E4B818FAQ37984189-A10D8361-46C1-4A24-A46C-5964A2BAEE72Q38594174-195D4734-352C-4BBF-B0BE-BC6C1A9504B7Q39372483-3BFA84A1-17B3-49E7-8161-2DD4BBBF8540Q40002235-930D1758-D3EB-4F5B-A825-10B1357D2A35Q41830553-6B16230C-2764-4552-B6C3-7341007C9631Q41906005-9FC31B06-701B-40B8-A6E4-8055CCA495FBQ41997785-D0903AD8-2ABA-49A1-937A-7C2F16D49017Q42626939-54219F46-A8F9-47EA-994F-78D19A59A5A9Q42927772-DB7A0670-C5CE-49AF-9E1E-4B7DF699355DQ45995429-F9132A7B-E43B-4E3B-B0D0-EA49EC464210Q46864959-9E59E855-8246-4442-AA06-C983E7315322Q48169745-C2D55791-B255-442E-8318-41EDFA0BBDA1Q48189307-EF0A8FEB-B5D5-4A5A-90EC-915D74E746DFQ48218659-D0477DCB-AB80-4919-B990-15B9E473CDE5
P50
description
Forscher
@de
investigador
@es
onderzoeker
@nl
researcher
@en
ricercatore
@it
研究員
@ja
研究者
@zh
name
Emmanuel S Antonarakis
@en
Emmanuel S Antonarakis
@nl
type
label
Emmanuel S Antonarakis
@en
Emmanuel S Antonarakis
@nl
prefLabel
Emmanuel S Antonarakis
@en
Emmanuel S Antonarakis
@nl
P106
P31
P496
0000-0003-0031-9655